EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Current perspectives on resistance to chimeric antigen receptor T‐cell therapy and strategies to improve efficacy in B‐cell lymphoma

Shin Yeu Ong, Yunxin Chen, Melinda Si Yun Tan, Aloysius Yew Leng Ho, William Ying Khee Hwang, Francesca Lorraine Wei Inng Lim

European Journal of Haematology · 2024

DOI: 10.1111/ejh.13964 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Haematology, 2024. Verfasst von Shin Yeu Ong und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, Singapore General Hospital, Singapore, Singapore. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Lymphoma, B-Cell. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although chimeric antigen receptor (CAR) T‐cell therapy has demonstrated remarkable efficacy in patients with chemo‐refractory B‐cell lymphoma, a significant portion is refractory or relapse. Resistance is a major barrier to improving treatment efficacy and long‐term survival in CAR T‐cell therapy, and clinicians have very limited tools to discriminate a priori patients who will or will not respond to treatment. While CD19‐negative relapses due to loss of target antigen is well described, it accounts for only about 30% of cases with treatment failure. Recent efforts have shed light on mechanisms of CD19‐positive relapse due to tumor intrinsic resistance, T‐cell quality/manufacturing, or CAR T‐cell exhaustion mediated by hostile tumor microenvironment. Here, we review the latest updates of preclinical and clinical trials to investigate the mechanisms of resistance and relapse post CAR T‐cell therapy in B cell lymphoma and discuss novel treatment strategies to overcome resistance as well as advances that are useful for a CAR T therapist to optimize and personalize CAR T‐cell therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenLymphoma, B-CellHumansImmunotherapy, AdoptiveReceptors, Antigen, T-CellAntigens, CD19RecurrenceCell- and Tissue-Based TherapyTumor Microenvironment

Stichwörter der Autor:innen

B-cell lymphomaCD19T cell exhaustionantigen escapechimeric antigen receptor

Substanzen

Receptors, Chimeric AntigenReceptors, Antigen, T-CellAntigens, CD19

Autor:innen und Institutionen

  • Department of Haematology, Singapore General Hospital, Singapore, Singapore.
  • Division of Medical Oncology, National Cancer Centre, Singapore, Singapore.

Zitieren

APA

Ong, S. Y., Chen, Y., Tan, M. S. Y., Ho, A. Y. L., Hwang, W. Y. K., & Lim, F. L. W. I. (2024). Current perspectives on resistance to chimeric antigen receptor T‐cell therapy and strategies to improve efficacy in B‐cell lymphoma. European Journal of Haematology. https://doi.org/10.1111/ejh.13964

Vancouver

Ong SY, Chen Y, Tan MSY, Ho AYL, Hwang WYK, Lim FLWI. Current perspectives on resistance to chimeric antigen receptor T‐cell therapy and strategies to improve efficacy in B‐cell lymphoma. European Journal of Haematology. 2024. doi:10.1111/ejh.13964

BibTeX
@article{Ong2024,
  author = {Ong, Shin Yeu and Chen, Yunxin and Tan, Melinda Si Yun and Ho, Aloysius Yew Leng and Hwang, William Ying Khee and Lim, Francesca Lorraine Wei Inng},
  title = {Current perspectives on resistance to chimeric antigen receptor T‐cell therapy and strategies to improve efficacy in B‐cell lymphoma},
  journal = {European Journal of Haematology},
  year = {2024},
  doi = {10.1111/ejh.13964}
}
Kostenlos starten →